secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K/A
Filed at:   2026-02-02T23:59:59+00:00
Accession:  0001193125-26-033771
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA completes acquisition of LAVA legacy assets; details Pfizer, Janssen programs and CVR terms
--------------------------------------------------------------------------------

- XOMA completed acquisition of LAVA legacy assets (EGFRd2, JNJ-89853413, LAVA-1266) on Nov 20, 2025.
- EGFRd2 (PF-8046052) outlicensed to Pfizer; potential milestones up to ~$650M; Phase 1 trial expected to complete 2029/2030.
- JNJ-89853413 outlicensed to Janssen; potential milestones up to ~$195M; Phase 1 started Jan 2025, expected completion Aug 2028.
- CVRs issued for 75% of net proceeds from future asset sales; XOMA valued CVRs at $0.00 due to early-stage uncertainty.
- XOMA will use commercially reasonable efforts for 2 years to sell or license the legacy assets for CVR holders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312526033771/0001193125-26-033771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312526033771/d135386d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-033771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer